nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer
|
Hofmann, Francesco |
|
2005 |
10 |
15 |
p. 1041-1047 7 p. |
artikel |
2 |
Cell cycle inhibitors key to neoangiogenesis
|
Sutherland, Stephani |
|
2005 |
10 |
15 |
p. 1015-1016 2 p. |
artikel |
3 |
Data management solutions for protein therapeutic research and development
|
Vielmetter, Jost |
|
2005 |
10 |
15 |
p. 1065-1071 7 p. |
artikel |
4 |
First clinical data on RNAi
|
Whelan, Jo |
|
2005 |
10 |
15 |
p. 1014-1015 2 p. |
artikel |
5 |
How can we avoid the productivity gap?
|
Carney, Steve |
|
2005 |
10 |
15 |
p. 1011-1013 3 p. |
artikel |
6 |
How many genomics targets can a portfolio afford?
|
Betz, Ulrich A.K. |
|
2005 |
10 |
15 |
p. 1057-1063 7 p. |
artikel |
7 |
Keynote review: Is declining innovation in the pharmaceutical industry a myth?
|
Schmid, Esther F. |
|
2005 |
10 |
15 |
p. 1031-1039 9 p. |
artikel |
8 |
Monitor – biology
|
Collin, Mattias |
|
2005 |
10 |
15 |
p. 1073- 1 p. |
artikel |
9 |
Monitor – chemistry
|
Sivaprakasam, Kannan |
|
2005 |
10 |
15 |
p. 1072- 1 p. |
artikel |
10 |
Optimizing the discovery organization for innovation
|
Sams-Dodd, Frank |
|
2005 |
10 |
15 |
p. 1049-1056 8 p. |
artikel |
11 |
Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine
|
Carney, Steve |
|
2005 |
10 |
15 |
p. 1017-1020 4 p. |
artikel |
12 |
Question: what do you call 500 scientists coming together to address the productivity gap? Answer: a start
|
Carney, Steve |
|
2005 |
10 |
15 |
p. 1025-1029 5 p. |
artikel |
13 |
Resisting resistance
|
Ewan, Scott |
|
2005 |
10 |
15 |
p. 1015- 1 p. |
artikel |
14 |
The future of antidepressants
|
Learner, Frances |
|
2005 |
10 |
15 |
p. 1021-1024 4 p. |
artikel |